表紙
市場調査レポート

ブラジルの医薬品市場の将来展望

Brazil Pharmaceutical Market Outlook 2018

発行 RNCOS E-Services Pvt. Ltd. 商品コード 321221
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ブラジルの医薬品市場の将来展望 Brazil Pharmaceutical Market Outlook 2018
出版日: 2014年12月14日 ページ情報: 英文 90 Pages
概要

ブラジルはラテンアメリカ最大、世界全体でも5番目に大きな医薬品市場となっています。政府の強力な支援や、巨大な医療サービス需要が、市場成長の主な要因となっています。世界各国の製薬企業が、今後最も有望な市場として、ブラジル市場の開拓を進めています。医療サービス全般にわたる整備計画の推進もまた、医薬品市場の成長に貢献しています。ブラジルの医薬品市場の規模は268億9000満米ドル(2013年現在)、また2013〜2018年の年平均成長率(CAGR)は14.5%に達する、と推計されています。部門別に見ると、OTC医薬品(一般薬)・ジェネリック医薬品の市場成長率が非常に高くなっています。また、国内大手企業で市場全体の約50%を占めています。

当レポートでは、ブラジルの医薬品市場について分析し、市場の全体的構造や最新動向、主な促進要因や解決すべき課題、政府の関連規制・政策、市場全体および各部門の動向見通し(今後5年間分)、市場の競争状態、企業合併・買収(M&A)の動き、主要企業のプロファイルなどを調査・考察しております。

第1章 アナリストの見解

第2章 分析手法

第3章 市場促進要因

  • 医療への公的・民間支出額
  • 治験件数の増加
  • 可処分所得の拡大
  • 人口の高齢化

第4章 市場の課題

  • 薬物治療の費用の高さ
  • 輸入薬への依存状況
  • 厳格な薬剤認証・規制法
  • 税負担の重さ

第5章 製薬産業の概要

第6章 市場の内訳

  • OTC(一般用)医薬品
    • 規制体制
  • ジェネリック医薬品
  • 処方薬

第7章 ブラジル国内の疾患治療分野

  • 腫瘍
  • 感染症
  • 心血管疾患・糖尿病
  • 中枢神経系(CNS)疾患

第8章 企業合併・買収(M&A)(2010年以降の大型案件)

第9章 競争環境

  • 国内系/外資系企業の市場シェア
  • 全体的な市場シェアの内訳

第10章 主要企業

  • EMS
  • Hypermarcas
  • Ache Laboratories
  • Eurofarma
  • Sanofi-Aventis
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer
  • Merck Group

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Brazil is considered as one of the most lucrative healthcare markets, accounting for the highest healthcare expenditure in Latin America. It is the largest pharmaceutical market in Latin America and the fifth largest globally. Strong government support and high healthcare services demand are two of the major factors propelling the country's pharmaceutical market. Drug makers are also keen to tap the Brazilian market because it is one of the most lucrative and fastest-growing pharma markets worldwide. Pharma companies such as Sanofi, Pfizer, Boehringer Ingelheim, Sun Pharma, GSK, etc., have been trying to expand their businesses in Latin America following acquisition of domestic manufactures.

The Brazilian Government has adopted several initiatives and implemented appropriate plans and policies that have resulted in the positive development of the country's overall healthcare services and facilities. In our latest research study "Brazil Pharmaceutical Market Outlook 2018", RNCOS' analysts have identified the market dynamics of major pharmaceutical segments such as Generics, OTC and Prescription Drugs. Accordingly, a study has been conducted for their current market sizes and forecasts for the next five years. The Pharmaceutical market, which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018.

RNCOS' analysis shows that the Over-the-Counter drug and Generic drug segments have been the fastest growing and are expected to surpass the branded medications market in the near future. Government support to encourage the domestic drug industry, rising healthcare expenditure, patent expiry, reduced taxations, high disposable incomes, etc., are few important drivers resulting in high growth in these segments. Further analysis includes current market statistics, key drivers stimulating each segment's growth, and future outlook of the segments.

EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively. These companies contributed around 50% of the domestic pharmaceutical market in 2013. Among the foreign players, Sanofi, Novartis and Roche have been generating a significant amount of revenue from the Brazilian market since the last three years.

The report, covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments. The topics covered in the report include: Pharmaceutical Production, Prescription Segment, OTC Segment, Therapeutic Segment as well as Mergers and Acquisitions. The report also presents an insight into the current industry trends, key market drivers, and government initiatives to enable the clients understand the market structure and its growth during the forecasted period. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Drivers

  • 3.1 Public and Private Expenditure on Healthcare
  • 3.2 Rising Number of Clinical Trials
  • 3.3 Rising Disposable Income
  • 3.4 Ageing Population

4. Market Challenges

  • 4.1 High Prices of Medications
  • 4.2 Dependence on Imported Drugs
  • 4.3 Stringent Drug Licensing and Regulatory Laws
  • 4.4 High Tax Burden

5. Pharmaceutical Industry Overview

6. Market Segmentation

  • 6.1 OTC Drug
    • 6.1.1 Regulatory Framework
  • 6.2 Generics
    • 6.2.1 Regulatory Framework
  • 6.3 Prescription Drug
    • 6.3.1 Regulatory Framework

7. Therapeutic Segments in Brazil

  • 7.1 Oncology
  • 7.2 Infectious Diseases
  • 7.3 Cardiovascular and Diabetes
  • 7.4 CNS Diseases

8. Mergers and Acquisitions (Premium Deals since 2010)

9. Competitive Landscape

  • 9.1 Share of Domestic Vs International Players
  • 9.2 Overall Market Share Breakdown

10. Key Players

  • 10.1 EMS
  • 10.2 Hypermarcas
  • 10.3 Ache Laboratories
  • 10.4 Eurofarma
  • 10.5 Sanofi-Aventis
  • 10.6 F. Hoffmann La Roche
  • 10.7 Novartis
  • 10.8 Pfizer
  • 10.9 Merck Group

List of Figures:

  • Figure 3-1: Expenditure on Health (% of GDP), 2008-2013
  • Figure 3-2: Total Expenditure on Health per capita (PPP int.US$), 2008-2013
  • Figure 3-3: Share of Government and Private Expenditure (2012)
  • Figure 3-4: Government Expenditure on Health (% of total expenditure), 2008-2012
  • Figure 3-5: Private Expenditure on Health (% of total expenditure), 2008-2012
  • Figure 3-6: Number of Clinical Trials (2008-2014)
  • Figure 3-7: Annual Disposable Income (Million US$), 2010-2014
  • Figure 3-8: Disposable Income Brackets (%), 2012
  • Figure 3-9: Population above 65 Years (Million), 2008-2013
  • Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2013)
  • Figure 5-2: Pharmaceutical Production (Million US$), 2011-2013
  • Figure 5-3: Pharmaceutical Production Share by Use (2013)
  • Figure 5-4: Pharmaceutical Production by Use (Million US$), 2012 & 2013
  • Figure 5-5: Pharmaceutical Production by Ingredients (Million US$), 2012 & 2013
  • Figure 5-6: Pharmaceutical Production Share by Ingredients (2013)
  • Figure 5-7: Pharmaceutical Trade (Million US$), 2011-2013
  • Figure 5-8: Pharmaceutical Market (Billion US$), 2013-2018
  • Figure 5-9: Pharmaceutical Sales Volume (Billion Units), 2008-2013
  • Figure 6-1: Pharmaceutical Market Share by Segments (2013)
  • Figure 6-2: Pharmaceutical Market Share by Segments (2018)
  • Figure 6-3: OTC Drugs Market (Billion US$), 2013-2018
  • Figure 6-4: OTC Market Segmentation by Category (2013)
  • Figure 6-5: Generics Market (Billion US$), 2013-2018
  • Figure 6-6: Generics Drug Sales by Volume (Million Units), 2008-2013
  • Figure 6-7: Generics Drug Laboratories (2010-2013)
  • Figure 6-8: Generics Drug Market by Country of Origin (%), 2013
  • Figure 6-9: Number of Generics Drugs Registered by Company (2013)
  • Figure 6-10: Prescription Drugs Market Segmentation (2013)
  • Figure 6-11: Prescription Drugs Market (Billion US$), 2013-2018
  • Figure 7-1: Number of HIV Cases Registered ('000), 2005 & 2013
  • Figure 7-2: HIV Infection Rate in Adult Population (%), 2013 & 2030
  • Figure 7-3: Diabetic Patients in Age Group 20-79 Years (Million), 2013 & 2030
  • Figure 9-1: Share of Domestic and International Players (2013)
  • Figure 9-2: Market Share of Leading Players in Brazilian Pharmaceutical Market (2013)
  • Figure 10-1: Hypermarcas - Revenue Share by Business Segments (2013)
  • Figure 10-2: Ache Laboratories - Revenue Share by Business Segments (2013)
  • Figure 10-3: Sanofi-Aventis - Revenue by Business Segments (Million US$), 2012 & 2013
  • Figure 10-4: Sanofi-Aventis - Revenue Share by Geographical Regions (2013)
  • Figure 10-5: Sanofi-Aventis - Revenue Share by Different Regions in Emerging Market (2013)
  • Figure 10-6: Roche - Revenue Share by Business Segments (2013)
  • Figure 10-7: Roche - Revenue Share by Therapeutic Segments (2013)
  • Figure 10-8: Roche - Pharmaceutical Revenue Share by Geographical Regions (2013)
  • Figure 10-9: Novartis - Revenue Share by Business Segments (2013)
  • Figure 10-10: Novartis - Pharmaceutical Revenue Share by Geographical Regions (2013)
  • Figure 10-11: Pfizer - Revenue Share by Business Segments (2013)
  • Figure 10-12: Pfizer - Revenue Share by Geographical Regions (2013)
  • Figure 10-13: Merck Group - Revenue Share of Biopharmaceuticals by Geographic Regions (2013)
  • Figure 10-14: Merck Group - Revenue Share of OTC by Geographic Regions (2013)

List of Tables:

  • Table 3-1: Household Disposable Income Brackets ('000), 2012
  • Table 5-1: Ranking of Medications by Sales (2013)
  • Table 6-1: Number of Generics Drugs by Country (2013)
  • Table 7-1: Prevalence of Overweight and Obesity by Gender (%), 2013
  • Table 10-1: Hypermarcas - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-2: Ache Laboratories - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-3: Novartis - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-4: Pfizer - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-5: Merck Group - Revenue by Business Segments (Million US$), 2012 & 2013
Back to Top